Novozymes reported soft Q3 19 numbers – missing estimates. Sales came in at DKK3,704m, up 1% on organic basis – driven by Household and Agriculture & Feed. EBIT came in at DKK852m with the associated margin at 23%. However, excluding on-offs, the underlying margin came in at 30%. Management re-iterated its FY 19 guidance: top-line growth of -2% to -0%, 27-28% EBIT margin and -5% to -0% net income growth. Following the soft Q3, we will be revising our estimates marginally downw
11 Dec 2019
No cure for the Bioenergy pain?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
No cure for the Bioenergy pain?
Novonesis A/S (Novozymes A/S) Class B (NZYM:WBO) | 0 0 2.6% | Mkt Cap: 80,754m
- Published:
11 Dec 2019 -
Author:
Virendra Chauhan -
Pages:
3
Novozymes reported soft Q3 19 numbers – missing estimates. Sales came in at DKK3,704m, up 1% on organic basis – driven by Household and Agriculture & Feed. EBIT came in at DKK852m with the associated margin at 23%. However, excluding on-offs, the underlying margin came in at 30%. Management re-iterated its FY 19 guidance: top-line growth of -2% to -0%, 27-28% EBIT margin and -5% to -0% net income growth. Following the soft Q3, we will be revising our estimates marginally downw